CLINICAL TRIALS PROFILE FOR VARICELLA VIRUS VACCINE LIVE

All Clinical Trials for varicella virus vaccine live

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00641446 ↗	Varicella Vaccination With Pulmicort	Completed	AstraZeneca	Phase 4	2001-10-01	A study to determine whether treatment with Pulmicort in children has any effect on the varicella vaccine
NCT01356004 ↗	Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis	Completed	Cairo University	Phase 4	2010-01-01	Immunotherapy was reported in the treatment of psoriasis. Treatment of resistant psoriasis may be difficult and cyclosporine can induce some remission. The investigators hypothesized that the combined use of live attenuated varicella vaccine as an adjuvant therapy to low dose cyclosporine in the treatment of severe resistant psoriasis can give positive responses.
NCT01474720 ↗	Zostavax in Systemic Lupus Erythematosus	Completed	Oklahoma Medical Research Foundation	Phase 1	2011-11-01	Individuals with systemic lupus erythematosus (SLE, lupus) appear to be at increased risk for the development of shingles, a painful reactivation of the varicella zoster virus that causes chicken pox. The investigators propose to study the immune response to commercially available Zostavax vaccine (shingles vaccine) in adult patients with SLE who have minimal disease activity and are on mild immunosuppressant medications, and to compare the immune response to that seen in healthy people following vaccination. Acceptable immunosuppressive drugs permitted in the study are those felt to be safe according to Centers for Disease Control guidelines. Ten healthy people and 10 SLE patients (all over 50 years of age) will be recruited to receive a single, standard dose of Zostavax. Blood samples and physical examination will be performed prior to injection, then 2,6,and 12 weeks following vaccination. All participants will receive active vaccine, there is no placebo group.
NCT01506661 ↗	Safety of Zostavax Vaccination in Rheumatoid Arthritis	Completed	Oklahoma Medical Research Foundation	Phase 1	2012-01-01	Herpes Zoster (shingles) is caused by reactivation of latent varicella zoster virus (VZV) that usually occurs decades following initial exposure. The risk of developing shingles increases with age. Shingles presents as a painful, itchy blistering rash that usually involves a single portion of the skin and lasts about 7-10 days. The risk of developing shingles increases with age in healthy people, and has been shown in some studies to be increased in people with rheumatoid arthritis and other autoimmune diseases. Zostavax, a live-attenuated vaccine against the varicella zoster virus, was first approved by the FDA for the prevention of Shingles among people 60 years and older, and is now approved for use in people aged 50 years and older. Because rheumatoid arthritis and some of the medications used to treat rheumatoid arthritis can impair the body's immune system, it is not known how much of an immune response can be generated in people with rheumatoid arthritis. The goals of this study are to measure the immune response after standard vaccination with Zostavax in people with rheumatoid arthritis in comparison to people with healthy immune systems. All participants will be 50 years old or older, and subjects with rheumatoid arthritis will not be eligible if they are taking certain biologic medications, including TNF inhibitors (Etanercept or Adalimumab). Ten healthy subjects and 10 subjects with rheumatoid arthritis will all receive a single vaccination with Zostavax, then will be followed for 12 weeks to assess the immune response and for the development of local rash or other potential side effects.
NCT01623596 ↗	Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.	Completed	Novartis Pharmaceuticals	Phase 4	2012-06-08	A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy. Patients will be be treatment naive or have only been treated with one class of DMT (Interferon beta preparation or glatiramer acetate) . Patients will be able to switch to different treatment for safety, efficacy, tolerability or convenience during the study. Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI.
NCT01953900 ↗	iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma	Active, not recruiting	Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1	2014-04-01	The purpose of this study is to find the largest safe dose of GD2-T cells (also called iC9-GD2-CAR-VZV-CTLs) in combination with a varicella zoster vaccine and lymohodepleting chemotherapy. Additionally, we will learn what the side effects of this treatment are and to see whether this therapy might help patients with advanced osteosarcoma and neuroblastoma. Because there is no standard treatment for recurrent/refractory osteosarcoma and neuroblastoma at this time or because the currently used treatments do not work fully in all cases, patients are being asked to volunteer to take part in a gene transfer research study using special immune cells. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat patients with cancers. They have shown promise, but have not been strong enough to cure most patients. Investigators have found from previous research that a new gene can be put into T cells that will make them recognize cancer cells and kill them. Investigators now want to see if a new gene can be put in these cells that will let the T cells recognize and kill sarcoma and neuroblastoma cells. The new gene is called a chimeric antigen receptor (CAR) and consists of an antibody called 14g2a that recognizes GD2, a protein that is found on sarcoma and neuroblastoma cells (GD2-CAR). In addition, it contains parts of the CD28 and OX40 genes which can stimulate T cells to make them live longer. Investigators have found that CAR-T cells can kill some of the tumor, but they don't last very long in the body and so the tumor eventually comes back. T cells that recognize the virus that causes chicken pox, varicella zoster virus (VZV), remain in the bloodstream for many years especially if they are stimulated or boosted by the VZV vaccine. Investigators will therefore insert the GD2-CAR gene into T cells that recognize VZV. These cells are called iC9-GD2-CAR-VZV-specific T cells but are referred to as GD2-T cells for simplicity.
NCT01953900 ↗	iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2014-04-01	The purpose of this study is to find the largest safe dose of GD2-T cells (also called iC9-GD2-CAR-VZV-CTLs) in combination with a varicella zoster vaccine and lymohodepleting chemotherapy. Additionally, we will learn what the side effects of this treatment are and to see whether this therapy might help patients with advanced osteosarcoma and neuroblastoma. Because there is no standard treatment for recurrent/refractory osteosarcoma and neuroblastoma at this time or because the currently used treatments do not work fully in all cases, patients are being asked to volunteer to take part in a gene transfer research study using special immune cells. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat patients with cancers. They have shown promise, but have not been strong enough to cure most patients. Investigators have found from previous research that a new gene can be put into T cells that will make them recognize cancer cells and kill them. Investigators now want to see if a new gene can be put in these cells that will let the T cells recognize and kill sarcoma and neuroblastoma cells. The new gene is called a chimeric antigen receptor (CAR) and consists of an antibody called 14g2a that recognizes GD2, a protein that is found on sarcoma and neuroblastoma cells (GD2-CAR). In addition, it contains parts of the CD28 and OX40 genes which can stimulate T cells to make them live longer. Investigators have found that CAR-T cells can kill some of the tumor, but they don't last very long in the body and so the tumor eventually comes back. T cells that recognize the virus that causes chicken pox, varicella zoster virus (VZV), remain in the bloodstream for many years especially if they are stimulated or boosted by the VZV vaccine. Investigators will therefore insert the GD2-CAR gene into T cells that recognize VZV. These cells are called iC9-GD2-CAR-VZV-specific T cells but are referred to as GD2-T cells for simplicity.

Clinical Trial Conditions for varicella virus vaccine live

Condition Name

Condition Name for varicella virus vaccine live
Intervention	Trials
Psoriasis	4
Rheumatoid Arthritis	3
Psoriatic Arthritis	3
Ankylosing Spondylitis	2

Condition MeSH

Condition MeSH for varicella virus vaccine live
Intervention	Trials
Herpes Zoster	6
Chickenpox	4
Arthritis	4
Psoriasis	4

Clinical Trial Locations for varicella virus vaccine live

Trials by Country

Trials by Country for varicella virus vaccine live
Location	Trials
United States	87
Canada	2
Egypt	1
Puerto Rico	1
Sweden	1

Trials by US State

Trials by US State for varicella virus vaccine live
Location	Trials
New York	5
California	4
Texas	4
West Virginia	3
Arizona	3

Clinical Trial Progress for varicella virus vaccine live

Clinical Trial Phase

Clinical Trial Phase for varicella virus vaccine live
Clinical Trial Phase	Trials
PHASE4	1
PHASE1	1
Phase 4	5

Clinical Trial Status

Clinical Trial Status for varicella virus vaccine live
Clinical Trial Phase	Trials
Completed	8
Active, not recruiting	3
Not yet recruiting	2

Clinical Trial Sponsors for varicella virus vaccine live

Sponsor Name

Sponsor Name for varicella virus vaccine live
Sponsor	Trials
Oregon Health and Science University	2
University of Alabama at Birmingham	2
Oklahoma Medical Research Foundation	2

Sponsor Type

Sponsor Type for varicella virus vaccine live
Sponsor	Trials
Other	17
Industry	8
NIH	3

Varicella Virus Vaccine Live: Clinical Trials Update, Market Analysis and Projections

Last updated: May 8, 2026

What is the reference product scope for “varicella virus vaccine live”?

“Varicella virus vaccine live” is a biologic category covering live attenuated varicella vaccines used to prevent primary varicella infection. Commercial portfolios in this category typically include:

• Varicella virus vaccine live, administered as a live attenuated vaccine, usually given as 1 dose or 2 doses depending on jurisdiction and schedule.
• Zoster formulations are distinct from varicella vaccines, even when derived from varicella-zoster virus strains; the market and clinical evidence differ. This analysis focuses on varicella (chickenpox) prevention products marketed as live attenuated varicella vaccines.

What do the current clinical-trials signals indicate for varicella vaccine live?

Data constraint: A complete and accurate “clinical trials update” requires a live query of registries (e.g., ClinicalTrials.gov, EU CTR) for current recruiting/active statuses, updated endpoints, and publication linkage. No registry feed or trial list was provided, so a precise update across trial phases, dosing arms, and timelines cannot be produced without risking factual errors.

What can be stated without registry-level granularity: live attenuated varicella vaccine evidence base is mature, with standard use established. Ongoing programs typically cluster around:

• Pediatric schedule optimization (single vs 2-dose programs, timing intervals, immunogenicity durability)
• Immunogenicity in special populations (immunocompromised-adjacent, household contacts, HIV-negative high-risk cohorts in eras where trials are still performed under strict criteria)
• Formulation and manufacturing comparability (lot-release bridging, stability, potency assays)
• Real-world effectiveness and safety follow-through (post-authorization surveillance studies rather than new phase 3 efficacy trials)

Because this response cannot include an accurate, trial-by-trial update without registry-sourced facts, it does not list individual trials, recruiting statuses, or dates.

Who are the key players in the varicella vaccine live market?

The market for live attenuated varicella vaccines is anchored by global manufacturers with established distribution through national immunization programs and private pediatric channels. The buyer and pricing dynamics are determined largely by:

• National immunization schedule mandates
• Tender structure and bulk purchasing
• Dose-count policies (1-dose vs 2-dose)
• Switching incentives tied to procurement contracts

Data constraint: Player-specific market shares, revenue figures, and SKU-level pricing require a current market report or registry-linked commercial dataset. None was provided. A precise competitive landscape with numbers cannot be assembled without fabricating.

How do immunization schedules drive demand for varicella vaccine live?

Demand is the product of birth cohort size and coverage penetration, multiplied by dose policy and adjusted for catch-up programs. The two most important levers:

1. Two-dose adoption increases unit demand versus single-dose schedules.
2. Catch-up campaigns for older children raise short-term demand and then normalize.

A practical model treats demand as:

• Annual vaccine doses = (newbirth cohort eligible for routine) × (coverage %) × (routine doses per child) + (catch-up cohort doses)
• Safety and scheduling guidance affect uptake: a stable safety profile sustains coverage, while administrative program design affects compliance.

What market size baseline and growth rate are supportable here?

Data constraint: A market analysis with specific USD market size, historical growth, and forecast CAGR requires cited sources. No market-sizing sources were provided. Without them, numerical projections would be speculative.

Therefore, the only defensible “projection” is directional, grounded in structural demand drivers rather than numeric forecasts.

What directional growth outlook is most likely?

The direction of demand for varicella vaccine live typically follows these forces:

• Continued expansion of routine immunization in additional geographies
• Steady increases where countries move from one dose to two doses
• Normalization post-uptake shocks in markets where coverage dipped during healthcare access disruptions
• Procurement-driven volatility where tender cycles create timing swings in shipments

Net: structural drivers point to mid-single-digit long-run volume growth in mature markets and higher in transitioning markets, but translating that into a credible CAGR or revenue forecast requires sourced sizing.

What pricing and reimbursement dynamics matter most?

Pricing is largely determined by:

• National tender prices for public programs
• Private market markups by region and channel
• Dose policy: two-dose programs double dose demand and influence price negotiations per fully immunized child
• Contract terms: warranty provisions, delivery schedules, and potency guarantees

A key business implication is that commercial success depends more on tender access and schedule inclusion than on differentiation in clinical endpoints, because live attenuated varicella vaccines are mature products.

How does clinical evidence translate into market access?

Market access in varicella vaccines tends to be stable once a country adopts:

• Routine inclusion for pediatric cohorts
• Dose-count policy
• Catch-up age windows

Any new clinical data that materially shifts market access would typically be:

• Evidence enabling schedule changes (e.g., two-dose interval changes or broader age approvals)
• Safety reassurance in specific populations
• Immunogenicity bridging supporting manufacturing or supply continuity

Absent registry-level updates, this analysis cannot quantify how recent trials alter access. In a matured category, updates are more likely to support regulatory stability and manufacturing continuity than to reopen major efficacy debates.

What is the likely investment and R&D focus for new entrants or line extensions?

In a mature live vaccine category, the highest-probability innovation pathways are:

• Next-generation live attenuated varicella candidates targeting improved immunogenicity or safety in real-world pediatric cohorts
• Combination approaches (co-formulations or programmatic bundling) that reduce visit burden and improve coverage
• Manufacturing improvements that reduce cost-of-goods and increase supply reliability for tender winners
• Real-world evidence packages tied to procurement requirements (safety monitoring plans, immunogenicity subset data)

What are the key business risks?

Core risks cluster in execution rather than clinical uncertainty:

• Schedule policy lock-in limits rapid switching once a national program selects a supplier
• Tender cycle timing risk creates revenue lumpiness
• Safety signal management risk: even mature vaccines face reputational and regulatory scrutiny if surveillance detects unexpected rare events
• Supply chain constraints risk for live attenuated products

Key Takeaways

• “Varicella virus vaccine live” demand is driven primarily by national immunization schedule adoption, especially shift to two-dose policies and catch-up campaigns.
• A detailed “clinical trials update” with current statuses, phases, and dates cannot be produced without registry-sourced inputs; the clinical evidence base is mature and current studies typically focus on immunogenicity durability, special populations, comparability, and post-authorization monitoring.
• Market forecasts in USD and CAGR terms require cited market-sizing sources; without those, this analysis provides directional outlook rather than numerical projections.
• Commercial success is most sensitive to tender access, schedule inclusion, and procurement cycle execution rather than breakthrough clinical differentiation.

---

FAQs

1) Is “varicella virus vaccine live” the same as shingles (zoster) vaccine?

No. Zoster vaccines target VZV reactivation and are distinct products with different clinical evidence, schedules, and market structures.

2) Why do two-dose schedules materially change market demand?

Two-dose adoption increases units per fully immunized child, which raises vaccine procurement volumes even if coverage stays constant.

3) What kinds of studies dominate post-authorization activity for mature varicella vaccines?

Typically immunogenicity, durability, bridging for manufacturing comparability, and real-world safety/effectiveness surveillance.

4) What is the main determinant of uptake in public programs?

National schedule inclusion and coverage implementation mechanics, including catch-up eligibility and procurement contract structures.

5) What are the most common reasons a vaccine supplier loses public tenders?

Price competitiveness, contract terms, supply reliability, and ability to meet administrative requirements tied to dosing schedules and delivery timelines.

---

References

[1] No sources were provided in the prompt for clinical-trial registry data or market sizing, so no citations can be listed.